Dementia, infections and vaccines: 30 years of controversy.
Alzheimer’s disease
Bacteria
Dementia
Infection
Virus
Journal
Aging clinical and experimental research
ISSN: 1720-8319
Titre abrégé: Aging Clin Exp Res
Pays: Germany
ID NLM: 101132995
Informations de publication
Date de publication:
Jun 2023
Jun 2023
Historique:
received:
04
03
2023
accepted:
21
03
2023
medline:
23
5
2023
pubmed:
10
5
2023
entrez:
9
5
2023
Statut:
ppublish
Résumé
This paper reports the proceedings of a virtual meeting convened by the European Interdisciplinary Council on Ageing (EICA), to discuss the involvement of infectious disorders in the pathogenesis of dementia and neurological disorders leading to dementia. We recap how our view of the infectious etiology of dementia has changed over the last 30 years in light of emerging evidence, and we present evidence in support of the implication of infection in dementia, notably Alzheimer's disease (AD). The bacteria and viruses thought to be responsible for neuroinflammation and neurological damage are reviewed. We then review the genetic basis for neuroinflammation and dementia, highlighting the genes that are currently the focus of investigation as potential targets for therapy. Next, we describe the antimicrobial hypothesis of dementia, notably the intriguing possibility that amyloid beta may itself possess antimicrobial properties. We further describe the clinical relevance of the gut-brain axis in dementia, the mechanisms by which infection can move from the intestine to the brain, and recent findings regarding dysbiosis patterns in patients with AD. We review the involvement of specific pathogens in neurological disorders, i.e. SARS-CoV-2, human immunodeficiency virus (HIV), herpes simplex virus type 1 (HSV1), and influenza. Finally, we look at the role of vaccination to prevent dementia. In conclusion, there is a large body of evidence supporting the involvement of various infectious pathogens in the pathogenesis of dementia, but large-scale studies with long-term follow-up are needed to elucidate the role that infection may play, especially before subclinical or clinical disease is present.
Identifiants
pubmed: 37160649
doi: 10.1007/s40520-023-02409-8
pii: 10.1007/s40520-023-02409-8
pmc: PMC10169152
doi:
Substances chimiques
Amyloid beta-Peptides
0
Vaccines
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
1145-1160Informations de copyright
© 2023. The Author(s).
Références
Doherty MT, Aris E, Servotte N et al (2022) Capturing the value of vaccination: impact of vaccine-preventable disease on hospitalization. Aging Clin Exp Res 34:1551–1561. https://doi.org/10.1007/s40520-022-02110-2
doi: 10.1007/s40520-022-02110-2
pubmed: 35633477
pmcid: 9142834
Gaillat J (2021) Where are the keys to improve vaccine uptake in adults and elders in European countries? Aging Clin Exp Res 33:1123–1131. https://doi.org/10.1007/s40520-019-01443-9
doi: 10.1007/s40520-019-01443-9
pubmed: 31900875
Schoevaerdts D, Sibille FX, Gavazzi G (2021) Infections in the older population: what do we know? Aging Clin Exp Res 33:689–701. https://doi.org/10.1007/s40520-019-01375-4
doi: 10.1007/s40520-019-01375-4
pubmed: 31656032
Onder G, Vetrano DL, Palmer K et al (2022) Italian guidelines on management of persons with multimorbidity and polypharmacy. Aging Clin Exp Res 34:989–996. https://doi.org/10.1007/s40520-022-02094-z
doi: 10.1007/s40520-022-02094-z
pubmed: 35249211
pmcid: 9135855
World Health Organization (2020) Global Health Estimates: Top 10 causes of death. Available at: https://www.who.int/data/global-health-estimates . Accessed 29 Jan 2023
Zuliani G, Gallerani M, Martellucci CA et al (2022) Dementia and in-hospital mortality: retrospective analysis of a nationwide administrative database of elderly subjects in Italy. Aging Clin Exp Res 34:1037–1045. https://doi.org/10.1007/s40520-021-02021-8
doi: 10.1007/s40520-021-02021-8
pubmed: 34796461
Itzhaki RF, Lathe R, Balin BJ et al (2016) Microbes and Alzheimer’s disease. J Alzheimers Dis 51:979–984. https://doi.org/10.3233/JAD-160152
doi: 10.3233/JAD-160152
pubmed: 26967229
pmcid: 5457904
Fulop T, Itzhaki RF, Balin BJ et al (2018) Role of microbes in the development of Alzheimer’s disease: state of the art—an international symposium presented at the 2017 IAGG Congress in San Francisco. Front Genet 9:362. https://doi.org/10.3389/fgene.2018.00362
doi: 10.3389/fgene.2018.00362
pubmed: 30250480
pmcid: 6139345
Vigasova D, Nemergut M, Liskova B et al (2021) Multi-pathogen infections and Alzheimer’s disease. Microb Cell Fact 20:25. https://doi.org/10.1186/s12934-021-01520-7
doi: 10.1186/s12934-021-01520-7
pubmed: 33509204
pmcid: 7844946
Panza F, Lozupone M, Solfrizzi V et al (2019) Time to test antibacterial therapy in Alzheimer’s disease. Brain 142:2905–2929. https://doi.org/10.1093/brain/awz244
doi: 10.1093/brain/awz244
pubmed: 31532495
Renvoize EB, Hambling MH, Pepper MD et al (1979) Possible association of Alzheimer’s disease with HLA-BW15 and cytomegalovirus infection. Lancet 1:1238. https://doi.org/10.1016/s0140-6736(79)91914-7
doi: 10.1016/s0140-6736(79)91914-7
pubmed: 87696
Barnes LL, Capuano AW, Aiello AE et al (2015) Cytomegalovirus infection and risk of Alzheimer disease in older black and white individuals. J Infect Dis 211:230–237. https://doi.org/10.1093/infdis/jiu437
doi: 10.1093/infdis/jiu437
pubmed: 25108028
Nimgaonkar VL, Yolken RH, Wang T et al (2016) Temporal cognitive decline associated with exposure to infectious agents in a population-based, aging cohort. Alzheimer Dis Assoc Disord 30:216–222. https://doi.org/10.1097/WAD.0000000000000133
doi: 10.1097/WAD.0000000000000133
pubmed: 26710257
pmcid: 4919236
Lurain NS, Hanson BA, Martinson J et al (2013) Virological and immunological characteristics of human cytomegalovirus infection associated with Alzheimer disease. J Infect Dis 208:564–572. https://doi.org/10.1093/infdis/jit210
doi: 10.1093/infdis/jit210
pubmed: 23661800
pmcid: 3719902
Tsai MC, Cheng WL, Sheu JJ et al (2017) Increased risk of dementia following herpes zoster ophthalmicus. PLoS ONE 12:e0188490. https://doi.org/10.1371/journal.pone.0188490
doi: 10.1371/journal.pone.0188490
pubmed: 29166672
pmcid: 5699837
Balin BJ, Gerard HC, Arking EJ et al (1998) Identification and localization of Chlamydia pneumoniae in the Alzheimer’s brain. Med Microbiol Immunol 187:23–42. https://doi.org/10.1007/s004300050071
doi: 10.1007/s004300050071
pubmed: 9749980
Little CS, Hammond CJ, MacIntyre A et al (2004) Chlamydia pneumoniae induces Alzheimer-like amyloid plaques in brains of BALB/c mice. Neurobiol Aging 25:419–429. https://doi.org/10.1016/S0197-4580(03)00127-1
doi: 10.1016/S0197-4580(03)00127-1
pubmed: 15013562
Maheshwari P, Eslick GD (2015) Bacterial infection and Alzheimer’s disease: a meta-analysis. J Alzheimers Dis 43:957–966. https://doi.org/10.3233/JAD-140621
doi: 10.3233/JAD-140621
pubmed: 25182736
Dominy SS, Lynch C, Ermini F et al (2019) Porphyromonas gingivalis in Alzheimer’s disease brains: evidence for disease causation and treatment with small-molecule inhibitors. Sci Adv 5:eaau3333. https://doi.org/10.1126/sciadv.aau3333
doi: 10.1126/sciadv.aau3333
pubmed: 30746447
pmcid: 6357742
Kamer AR, Craig RG, Dasanayake AP et al (2008) Inflammation and Alzheimer’s disease: possible role of periodontal diseases. Alzheimers Dement 4:242–250. https://doi.org/10.1016/j.jalz.2007.08.004
doi: 10.1016/j.jalz.2007.08.004
pubmed: 18631974
Kamer AR, Dasanayake AP, Craig RG et al (2008) Alzheimer’s disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. J Alzheimers Dis 13:437–449. https://doi.org/10.3233/jad-2008-13408
doi: 10.3233/jad-2008-13408
pubmed: 18487851
Sparks Stein P, Steffen MJ, Smith C et al (2012) Serum antibodies to periodontal pathogens are a risk factor for Alzheimer’s disease. Alzheimers Dement 8:196–203. https://doi.org/10.1016/j.jalz.2011.04.006
doi: 10.1016/j.jalz.2011.04.006
pubmed: 22546352
Beydoun MA, Beydoun HA, Weiss J et al (2021) Helicobacter pylori, periodontal pathogens, and their interactive association with incident all-cause and Alzheimer’s disease dementia in a large national survey. Mol Psychiatry 26:6038–6053. https://doi.org/10.1038/s41380-020-0736-2
doi: 10.1038/s41380-020-0736-2
pubmed: 32366948
Loy CT, Schofield PR, Turner AM et al (2014) Genetics of dementia. Lancet 383:828–840. https://doi.org/10.1016/S0140-6736(13)60630-3
doi: 10.1016/S0140-6736(13)60630-3
pubmed: 23927914
Leonenko G, Baker E, Stevenson-Hoare J et al (2021) Identifying individuals with high risk of Alzheimer’s disease using polygenic risk scores. Nat Commun 12:4506. https://doi.org/10.1038/s41467-021-24082-z
doi: 10.1038/s41467-021-24082-z
pubmed: 34301930
pmcid: 8302739
Bellenguez C, Kucukali F, Jansen IE et al (2022) New insights into the genetic etiology of Alzheimer’s disease and related dementias. Nat Genet 54:412–436. https://doi.org/10.1038/s41588-022-01024-z
doi: 10.1038/s41588-022-01024-z
pubmed: 35379992
pmcid: 9005347
Dourlen P, Kilinc D, Malmanche N et al (2019) The new genetic landscape of Alzheimer’s disease: from amyloid cascade to genetically driven synaptic failure hypothesis? Acta Neuropathol 138:221–236. https://doi.org/10.1007/s00401-019-02004-0
doi: 10.1007/s00401-019-02004-0
pubmed: 30982098
pmcid: 6660578
Gan L, Cookson MR, Petrucelli L et al (2018) Converging pathways in neurodegeneration, from genetics to mechanisms. Nat Neurosci 21:1300–1309. https://doi.org/10.1038/s41593-018-0237-7
doi: 10.1038/s41593-018-0237-7
pubmed: 30258237
pmcid: 6278826
Boillee S, Yamanaka K, Lobsiger CS et al (2006) Onset and progression in inherited ALS determined by motor neurons and microglia. Science 312:1389–1392. https://doi.org/10.1126/science.1123511
doi: 10.1126/science.1123511
pubmed: 16741123
Lall D, Lorenzini I, Mota TA et al (2021) C9orf72 deficiency promotes microglial-mediated synaptic loss in aging and amyloid accumulation. Neuron 109:22752291 e2278. https://doi.org/10.1016/j.neuron.2021.05.020
doi: 10.1016/j.neuron.2021.05.020
Nguyen AT, Wang K, Hu G et al (2020) APOE and TREM2 regulate amyloid-responsive microglia in Alzheimer’s disease. Acta Neuropathol 140:477–493. https://doi.org/10.1007/s00401-020-02200-3
doi: 10.1007/s00401-020-02200-3
pubmed: 32840654
pmcid: 7520051
Goutman SA, Hardiman O, Al-Chalabi A et al (2022) Emerging insights into the complex genetics and pathophysiology of amyotrophic lateral sclerosis. Lancet Neurol 21:465–479. https://doi.org/10.1016/S1474-4422(21)00414-2
doi: 10.1016/S1474-4422(21)00414-2
pubmed: 35334234
pmcid: 9513754
Casaletto KB, Nichols E, Aslanyan V et al (2022) Sex-specific effects of microglial activation on Alzheimer’s disease proteinopathy in older adults. Brain 145:3536–3545. https://doi.org/10.1093/brain/awac257
doi: 10.1093/brain/awac257
pubmed: 35869598
Bernier RA, Banks SJ, Panizzon MS et al (2022) The neuroinflammatory marker sTNFR2 relates to worse cognition and tau in women across the Alzheimer’s disease spectrum. Alzheimers Dement (Amst) 14:e12284. https://doi.org/10.1002/dad2.12284
doi: 10.1002/dad2.12284
pubmed: 35386474
Jay TR, von Saucken VE, Landreth GE (2017) TREM2 in neurodegenerative diseases. Mol Neurodegener 12:56. https://doi.org/10.1186/s13024-017-0197-5
doi: 10.1186/s13024-017-0197-5
pubmed: 28768545
pmcid: 5541421
Yeh FL, Hansen DV, Sheng M (2017) TREM2, microglia, and neurodegenerative diseases. Trends Mol Med 23:512–533. https://doi.org/10.1016/j.molmed.2017.03.008
doi: 10.1016/j.molmed.2017.03.008
pubmed: 28442216
Lozupone M, Imbimbo BP, Balducci C et al (2023) Does the imbalance in the apolipoprotein E isoforms underlie the pathophysiological process of sporadic Alzheimer’s disease? Alzheimers Dement 19:353–368. https://doi.org/10.1002/alz.12728
doi: 10.1002/alz.12728
pubmed: 35900209
Jian J, Li G, Hettinghouse A et al (2018) Progranulin: a key player in autoimmune diseases. Cytokine 101:48–55. https://doi.org/10.1016/j.cyto.2016.08.007
doi: 10.1016/j.cyto.2016.08.007
pubmed: 27527809
Lin J, Yang S, Wang C et al (2022) Prediction of Alzheimer’s disease using patterns of methylation levels in key immunologic-related genes. J Alzheimers Dis 90:783–794. https://doi.org/10.3233/JAD-220701
doi: 10.3233/JAD-220701
pubmed: 36189598
pmcid: 9697046
Hinderer C, Miller R, Dyer C et al (2020) Adeno-associated virus serotype 1-based gene therapy for FTD caused by GRN mutations. Ann Clin Transl Neurol 7:1843–1853. https://doi.org/10.1002/acn3.51165
doi: 10.1002/acn3.51165
pubmed: 32937039
pmcid: 7545603
Goldeck D, Witkowski JM, Fulop T et al (2016) Peripheral immune signatures in Alzheimer disease. Curr Alzheimer Res 13:739–749. https://doi.org/10.2174/1567205013666160222112444
doi: 10.2174/1567205013666160222112444
pubmed: 26899580
Jeong H, Shin H, Hong S et al (2022) Physiological roles of monomeric amyloid-beta and implications for Alzheimer’s disease therapeutics. Exp Neurobiol 31:65–88. https://doi.org/10.5607/en22004
doi: 10.5607/en22004
pubmed: 35673997
pmcid: 9194638
Munawara U, Catanzaro M, Xu W et al (2021) Hyperactivation of monocytes and macrophages in MCI patients contributes to the progression of Alzheimer’s disease. Immun Ageing 18:29. https://doi.org/10.1186/s12979-021-00236-x
doi: 10.1186/s12979-021-00236-x
pubmed: 34154615
pmcid: 8215492
Buckley MW, McGavern DB (2022) Immune dynamics in the CNS and its barriers during homeostasis and disease. Immunol Rev 306:58–75. https://doi.org/10.1111/imr.13066
doi: 10.1111/imr.13066
pubmed: 35067941
pmcid: 8852772
Chen D, Liu X, Chen Y et al (2022) Amyloid peptides with antimicrobial and/or microbial agglutination activity. Appl Microbiol Biotechnol 106:7711–7720. https://doi.org/10.1007/s00253-022-12246-w
doi: 10.1007/s00253-022-12246-w
pubmed: 36322251
pmcid: 9628408
Moir RD, Lathe R, Tanzi RE (2018) The antimicrobial protection hypothesis of Alzheimer’s disease. Alzheimers Dement 14:1602–1614. https://doi.org/10.1016/j.jalz.2018.06.3040
doi: 10.1016/j.jalz.2018.06.3040
pubmed: 30314800
Ticinesi A, Nouvenne A, Tana C et al (2018) The impact of intestinal microbiota on bio-medical research: definitions, techniques and physiology of a “new frontier.” Acta Biomed 89:52–59. https://doi.org/10.23750/abm.v89i9-S.7906
doi: 10.23750/abm.v89i9-S.7906
pubmed: 30561396
Arumugam M, Raes J, Pelletier E et al (2011) Enterotypes of the human gut microbiome. Nature 473:174–180. https://doi.org/10.1038/nature09944
doi: 10.1038/nature09944
pubmed: 21508958
pmcid: 3728647
Human Microbiome Project C (2012) Structure, function and diversity of the healthy human microbiome. Nature 486:207–214. https://doi.org/10.1038/nature11234
doi: 10.1038/nature11234
Sommer F, Anderson JM, Bharti R et al (2017) The resilience of the intestinal microbiota influences health and disease. Nat Rev Microbiol 15:630–638. https://doi.org/10.1038/nrmicro.2017.58
doi: 10.1038/nrmicro.2017.58
pubmed: 28626231
Dinan TG, Cryan JF (2017) Gut instincts: microbiota as a key regulator of brain development, ageing and neurodegeneration. J Physiol 595:489–503. https://doi.org/10.1113/JP273106
doi: 10.1113/JP273106
pubmed: 27641441
Rukavina Mikusic NL, Kouyoumdzian NM, Choi MR (2020) Gut microbiota and chronic kidney disease: evidences and mechanisms that mediate a new communication in the gastrointestinal-renal axis. Pflugers Arch 472:303–320. https://doi.org/10.1007/s00424-020-02352-x
doi: 10.1007/s00424-020-02352-x
pubmed: 32064574
Ticinesi A, Milani C, Lauretani F et al (2017) Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep 7:11102. https://doi.org/10.1038/s41598-017-10734-y
doi: 10.1038/s41598-017-10734-y
pubmed: 28894183
pmcid: 5593887
Wilmanski T, Diener C, Rappaport N et al (2021) Gut microbiome pattern reflects healthy ageing and predicts survival in humans. Nat Metab 3:274–286. https://doi.org/10.1038/s42255-021-00348-0
doi: 10.1038/s42255-021-00348-0
pubmed: 33619379
pmcid: 8169080
Strasser B, Wolters M, Weyh C et al (2021) The effects of lifestyle and diet on gut microbiota composition, inflammation and muscle performance in our aging society. Nutrients. https://doi.org/10.3390/nu13062045
doi: 10.3390/nu13062045
pubmed: 35010961
pmcid: 8746949
Rutsch A, Kantsjo JB, Ronchi F (2020) The gut-brain axis: how microbiota and host inflammasome influence brain physiology and pathology. Front Immunol 11:604179. https://doi.org/10.3389/fimmu.2020.604179
doi: 10.3389/fimmu.2020.604179
pubmed: 33362788
pmcid: 7758428
Bonaz B, Bazin T, Pellissier S (2018) The vagus nerve at the interface of the microbiota-gut-brain axis. Front Neurosci 12:49. https://doi.org/10.3389/fnins.2018.00049
doi: 10.3389/fnins.2018.00049
pubmed: 29467611
pmcid: 5808284
Bairamian D, Sha S, Rolhion N et al (2022) Microbiota in neuroinflammation and synaptic dysfunction: a focus on Alzheimer’s disease. Mol Neurodegener 17:19. https://doi.org/10.1186/s13024-022-00522-2
doi: 10.1186/s13024-022-00522-2
pubmed: 35248147
pmcid: 8898063
Heneka MT, Carson MJ, El Khoury J et al (2015) Neuroinflammation in Alzheimer’s disease. Lancet Neurol 14:388–405. https://doi.org/10.1016/S1474-4422(15)70016-5
doi: 10.1016/S1474-4422(15)70016-5
pubmed: 25792098
pmcid: 5909703
Yadav P, Lee YH, Panday H et al (2022) Implications of microorganisms in Alzheimer’s disease. Curr Issues Mol Biol 44:4584–4615. https://doi.org/10.3390/cimb44100314
doi: 10.3390/cimb44100314
pubmed: 36286029
pmcid: 9600878
Sweeney MD, Sagare AP, Zlokovic BV (2018) Blood-brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders. Nat Rev Neurol 14:133–150. https://doi.org/10.1038/nrneurol.2017.188
doi: 10.1038/nrneurol.2017.188
pubmed: 29377008
pmcid: 5829048
Carloni S, Rescigno M (2022) Unveiling the gut-brain axis: structural and functional analogies between the gut and the choroid plexus vascular and immune barriers. Semin Immunopathol 44:869–882. https://doi.org/10.1007/s00281-022-00955-3
doi: 10.1007/s00281-022-00955-3
pubmed: 35861857
pmcid: 9301898
Carloni S, Bertocchi A, Mancinelli S et al (2021) Identification of a choroid plexus vascular barrier closing during intestinal inflammation. Science 374:439–448. https://doi.org/10.1126/science.abc6108
doi: 10.1126/science.abc6108
pubmed: 34672740
Canfora EE, Jocken JW, Blaak EE (2015) Short-chain fatty acids in control of body weight and insulin sensitivity. Nat Rev Endocrinol 11:577–591. https://doi.org/10.1038/nrendo.2015.128
doi: 10.1038/nrendo.2015.128
pubmed: 26260141
Qian XH, Xie RY, Liu XL et al (2022) Mechanisms of short-chain fatty acids derived from gut microbiota in Alzheimer’s disease. Aging Dis 13:1252–1266. https://doi.org/10.14336/AD.2021.1215
doi: 10.14336/AD.2021.1215
pubmed: 35855330
pmcid: 9286902
Erny D, Dokalis N, Mezo C et al (2021) Microbiota-derived acetate enables the metabolic fitness of the brain innate immune system during health and disease. Cell Metab 33:2260–22762267. https://doi.org/10.1016/j.cmet.2021.10.010
doi: 10.1016/j.cmet.2021.10.010
pubmed: 34731656
Colombo AV, Sadler RK, Llovera G et al (2021) Microbiota-derived short chain fatty acids modulate microglia and promote Abeta plaque deposition. Elife. https://doi.org/10.7554/eLife.59826
doi: 10.7554/eLife.59826
pubmed: 33845942
pmcid: 8043748
Ueda A, Shinkai S, Shiroma H et al (2021) Identification of Faecalibacterium prausnitzii strains for gut microbiome-based intervention in Alzheimer’s-type dementia. Cell Rep Med 2:100398. https://doi.org/10.1016/j.xcrm.2021.100398
doi: 10.1016/j.xcrm.2021.100398
pubmed: 34622235
pmcid: 8484692
Zhu Z, Ma X, Wu J et al (2022) Altered gut microbiota and its clinical relevance in mild cognitive impairment and Alzheimer’s disease: Shanghai aging study and shanghai memory study. Nutrients. https://doi.org/10.3390/nu14193959
doi: 10.3390/nu14193959
pubmed: 36615779
pmcid: 9782010
Strasser B, Ticinesi A (2023) Intestinal microbiome in normal ageing, frailty and cognition decline. Curr Opin Clin Nutr Metab Care 26:8–16. https://doi.org/10.1097/MCO.0000000000000878
doi: 10.1097/MCO.0000000000000878
pubmed: 36102345
Kaiyrlykyzy A, Kozhakhmetov S, Babenko D et al (2022) Study of gut microbiota alterations in Alzheimer’s dementia patients from Kazakhstan. Sci Rep 12:15115. https://doi.org/10.1038/s41598-022-19393-0
doi: 10.1038/s41598-022-19393-0
pubmed: 36068280
pmcid: 9448737
Kruger JF, Hillesheim E, Pereira A et al (2021) Probiotics for dementia: a systematic review and meta-analysis of randomized controlled trials. Nutr Rev 79:160–170. https://doi.org/10.1093/nutrit/nuaa037
doi: 10.1093/nutrit/nuaa037
pubmed: 32556236
Li X, Lv C, Song J et al (2021) Effect of probiotic supplementation on cognitive function and metabolic status in mild cognitive impairment and Alzheimer’s disease: a meta-analysis. Front Nutr 8:757673. https://doi.org/10.3389/fnut.2021.757673
doi: 10.3389/fnut.2021.757673
pubmed: 34957177
pmcid: 8692377
Ghosh TS, Rampelli S, Jeffery IB et al (2020) Mediterranean diet intervention alters the gut microbiome in older people reducing frailty and improving health status: the NU-AGE 1-year dietary intervention across five European countries. Gut 69:1218–1228. https://doi.org/10.1136/gutjnl-2019-319654
doi: 10.1136/gutjnl-2019-319654
pubmed: 32066625
Koblinsky ND, Power KA, Middleton L et al (2022) The role of the gut microbiome in diet and exercise effects on cognition: a review of the intervention literature. J Gerontol A Biol Sci Med Sci. https://doi.org/10.1093/gerona/glac166
doi: 10.1093/gerona/glac166
pmcid: 9951060
Ticinesi A, Mancabelli L, Carnevali L et al (2022) Interaction between diet and microbiota in the pathophysiology of Alzheimer’s disease: focus on polyphenols and dietary fibers. J Alzheimers Dis 86:961–982. https://doi.org/10.3233/JAD-215493
doi: 10.3233/JAD-215493
pubmed: 35147544
Ashraf UM, Abokor AA, Edwards JM et al (2021) SARS-CoV-2, ACE2 expression, and systemic organ invasion. Physiol Genom 53:51–60. https://doi.org/10.1152/physiolgenomics.00087.2020
doi: 10.1152/physiolgenomics.00087.2020
Iwasaki M, Saito J, Zhao H et al (2021) Inflammation triggered by SARS-CoV-2 and ACE2 augment drives multiple organ failure of severe COVID-19: molecular mechanisms and implications. Inflammation 44:13–34. https://doi.org/10.1007/s10753-020-01337-3
doi: 10.1007/s10753-020-01337-3
pubmed: 33029758
Chen X, Laurent S, Onur OA et al (2021) A systematic review of neurological symptoms and complications of COVID-19. J Neurol 268:392–402. https://doi.org/10.1007/s00415-020-10067-3
doi: 10.1007/s00415-020-10067-3
pubmed: 32691236
Guadarrama-Ortiz P, Choreno-Parra JA, Sanchez-Martinez CM et al (2020) Neurological aspects of SARS-CoV-2 infection: mechanisms and manifestations. Front Neurol 11:1039. https://doi.org/10.3389/fneur.2020.01039
doi: 10.3389/fneur.2020.01039
pubmed: 33013675
pmcid: 7499054
Sollmann N, Beer AJ, Kirchhoff F (2022) SARS-CoV-2 infection and the brain: direct evidence for brain changes in milder cases. Signal Transduct Target Ther 7:230. https://doi.org/10.1038/s41392-022-01072-1
doi: 10.1038/s41392-022-01072-1
pubmed: 35817774
pmcid: 9272648
Nalbandian A, Sehgal K, Gupta A et al (2021) Post-acute COVID-19 syndrome. Nat Med 27:601–615. https://doi.org/10.1038/s41591-021-01283-z
doi: 10.1038/s41591-021-01283-z
pubmed: 33753937
pmcid: 8893149
Groff D, Sun A, Ssentongo AE et al (2021) Short-term and long-term rates of postacute sequelae of SARS-CoV-2 infection: a systematic review. JAMA Netw Open 4:e2128568. https://doi.org/10.1001/jamanetworkopen.2021.28568
doi: 10.1001/jamanetworkopen.2021.28568
pubmed: 34643720
pmcid: 8515212
Garg M, Maralakunte M, Garg S et al (2021) The conundrum of ‘Long-COVID-19’: a narrative review. Int J Gen Med 14:2491–2506. https://doi.org/10.2147/IJGM.S316708
doi: 10.2147/IJGM.S316708
pubmed: 34163217
pmcid: 8214209
Oguz SH, Koca M, Yildiz BO (2022) Aging versus youth: endocrine aspects of vulnerability for COVID-19. Rev Endocr Metab Disord 23:185–204. https://doi.org/10.1007/s11154-021-09656-y
doi: 10.1007/s11154-021-09656-y
pubmed: 33860905
Itzhaki RF (2023) COVID-19 and Alzheimer’s disease: what is the connection? J Alzheimers Dis 91:1273–1276. https://doi.org/10.3233/JAD-220955
doi: 10.3233/JAD-220955
pubmed: 36591656
Wang L, Davis PB, Volkow ND et al (2022) Association of COVID-19 with new-onset Alzheimer’s disease. J Alzheimers Dis 89:411–414. https://doi.org/10.3233/JAD-220717
doi: 10.3233/JAD-220717
pubmed: 35912749
Mattson MP (2015) Late-onset dementia: a mosaic of prototypical pathologies modifiable by diet and lifestyle. NPJ Aging Mech Dis 1:15003. https://doi.org/10.1038/npjamd.2015.3
doi: 10.1038/npjamd.2015.3
pubmed: 28642821
pmcid: 5478237
Tavassoly O, Safavi F, Tavassoly I (2020) Seeding brain protein aggregation by SARS-CoV-2 as a possible long-term complication of COVID-19 infection. ACS Chem Neurosci 11:3704–3706. https://doi.org/10.1021/acschemneuro.0c00676
doi: 10.1021/acschemneuro.0c00676
pubmed: 33147014
Hsu PC, Shahed-Al-Mahmud M (2022) SARS-CoV-2 mediated neurological disorders in COVID-19: measuring the pathophysiology and immune response. Life Sci 308:120981. https://doi.org/10.1016/j.lfs.2022.120981
doi: 10.1016/j.lfs.2022.120981
pubmed: 36150465
pmcid: 9490490
Guedj E, Campion JY, Dudouet P et al (2021) (18)F-FDG brain PET hypometabolism in patients with long COVID. Eur J Nucl Med Mol Imaging 48:2823–2833. https://doi.org/10.1007/s00259-021-05215-4
doi: 10.1007/s00259-021-05215-4
pubmed: 33501506
pmcid: 7837643
Douaud G, Lee S, Alfaro-Almagro F et al (2022) SARS-CoV-2 is associated with changes in brain structure in UK Biobank. Nature 604:697–707. https://doi.org/10.1038/s41586-022-04569-5
doi: 10.1038/s41586-022-04569-5
pubmed: 35255491
pmcid: 9046077
UNAIDS (2021) Global HIV & AIDS Statistics - Fact Sheet. Available at: https://www.unaids.org/sites/default/files/media_asset/UNAIDS_FactSheet_en.pdf . Accessed 31 Jan 2023
Kopstein M, Mohlman DJ (2022) HIV-1 encephalopathy and aids dementia complex. StatPearls, Treasure Island
Antinori A, Arendt G, Becker JT et al (2007) Updated research nosology for HIV-associated neurocognitive disorders. Neurology 69:1789–1799. https://doi.org/10.1212/01.WNL.0000287431.88658.8b
doi: 10.1212/01.WNL.0000287431.88658.8b
pubmed: 17914061
Haddow LJ, Laverick R, Daskalopoulou M et al (2018) Multicenter European prevalence study of neurocognitive impairment and associated factors in HIV positive patients. AIDS Behav 22:1573–1583. https://doi.org/10.1007/s10461-017-1683-z
doi: 10.1007/s10461-017-1683-z
pubmed: 28144792
Wang Y, Liu M, Lu Q et al (2020) Global prevalence and burden of HIV-associated neurocognitive disorder: a meta-analysis. Neurology 95:e2610–e2621. https://doi.org/10.1212/WNL.0000000000010752
doi: 10.1212/WNL.0000000000010752
pubmed: 32887786
Trunfio M, Vai D, Montrucchio C et al (2018) Diagnostic accuracy of new and old cognitive screening tools for HIV-associated neurocognitive disorders. HIV Med. https://doi.org/10.1111/hiv.12622
doi: 10.1111/hiv.12622
pubmed: 29761877
Vassallo M, Fabre R, Durant J et al (2017) A decreasing CD4/CD8 ratio over time and lower CSF-penetrating antiretroviral regimens are associated with a higher risk of neurocognitive deterioration, independently of viral replication. J Neurovirol 23:216–225. https://doi.org/10.1007/s13365-016-0490-z
doi: 10.1007/s13365-016-0490-z
pubmed: 27815816
Zayyad Z, Spudich S (2015) Neuropathogenesis of HIV: from initial neuroinvasion to HIV-associated neurocognitive disorder (HAND). Curr HIV/AIDS Rep 12:16–24. https://doi.org/10.1007/s11904-014-0255-3
doi: 10.1007/s11904-014-0255-3
pubmed: 25604237
pmcid: 4741099
Hategan A, Bianchet MA, Steiner J et al (2017) HIV Tat protein and amyloid-beta peptide form multifibrillar structures that cause neurotoxicity. Nat Struct Mol Biol 24:379–386. https://doi.org/10.1038/nsmb.3379
doi: 10.1038/nsmb.3379
pubmed: 28218748
pmcid: 5383535
Rempel HC, Pulliam L (2005) HIV-1 Tat inhibits neprilysin and elevates amyloid beta. AIDS 19:127–135. https://doi.org/10.1097/00002030-200501280-00004
doi: 10.1097/00002030-200501280-00004
pubmed: 15668537
Green DA, Masliah E, Vinters HV et al (2005) Brain deposition of beta-amyloid is a common pathologic feature in HIV positive patients. AIDS 19:407–411. https://doi.org/10.1097/01.aids.0000161770.06158.5c
doi: 10.1097/01.aids.0000161770.06158.5c
pubmed: 15750394
Fulop T, Witkowski JM, Larbi A et al (2019) Does HIV infection contribute to increased beta-amyloid synthesis and plaque formation leading to neurodegeneration and Alzheimer’s disease? J Neurovirol 25:634–647. https://doi.org/10.1007/s13365-019-00732-3
doi: 10.1007/s13365-019-00732-3
pubmed: 30868421
Chiodi F, Keys B, Albert J et al (1992) Human immunodeficiency virus type 1 is present in the cerebrospinal fluid of a majority of infected individuals. J Clin Microbiol 30:1768–1771. https://doi.org/10.1128/jcm.30.7.1768-1771.1992
doi: 10.1128/jcm.30.7.1768-1771.1992
pubmed: 1629333
pmcid: 265378
Ferretti F, Gisslen M, Cinque P et al (2015) Cerebrospinal fluid HIV escape from antiretroviral therapy. Curr HIV/AIDS Rep 12:280–288. https://doi.org/10.1007/s11904-015-0267-7
doi: 10.1007/s11904-015-0267-7
pubmed: 25860317
Perez-Valero I, Ellis R, Heaton R et al (2019) Cerebrospinal fluid viral escape in aviremic HIV-infected patients receiving antiretroviral therapy: prevalence, risk factors and neurocognitive effects. AIDS 33:475–481. https://doi.org/10.1097/QAD.0000000000002074
doi: 10.1097/QAD.0000000000002074
pubmed: 30702516
Soontornniyomkij V, Umlauf A, Soontornniyomkij B et al (2018) Association of antiretroviral therapy with brain aging changes among HIV-infected adults. AIDS 32:2005–2015. https://doi.org/10.1097/QAD.0000000000001927
doi: 10.1097/QAD.0000000000001927
pubmed: 29912063
Calcagno A, Atzori C, Romito A et al (2016) Blood brain barrier impairment is associated with cerebrospinal fluid markers of neuronal damage in HIV-positive patients. J Neurovirol 22:88–92. https://doi.org/10.1007/s13365-015-0371-x
doi: 10.1007/s13365-015-0371-x
pubmed: 26246357
Hermansson L, Yilmaz A, Axelsson M et al (2019) Cerebrospinal fluid levels of glial marker YKL-40 strongly associated with axonal injury in HIV infection. J Neuroinflammation 16:16. https://doi.org/10.1186/s12974-019-1404-9
doi: 10.1186/s12974-019-1404-9
pubmed: 30678707
pmcid: 6345016
Anesten B, Zetterberg H, Nilsson S et al (2021) Effect of antiretroviral treatment on blood-brain barrier integrity in HIV-1 infection. BMC Neurol 21:494. https://doi.org/10.1186/s12883-021-02527-8
doi: 10.1186/s12883-021-02527-8
pubmed: 34937542
pmcid: 8693475
Rahimy E, Li FY, Hagberg L et al (2017) Blood-brain barrier disruption is initiated during primary HIV infection and not rapidly altered by antiretroviral therapy. J Infect Dis 215:1132–1140. https://doi.org/10.1093/infdis/jix013
doi: 10.1093/infdis/jix013
pubmed: 28368497
pmcid: 5426376
Calcagno A, Celani L, Trunfio M et al (2021) Alzheimer dementia in people living with HIV. Neurol Clin Pract 11:e627–e633. https://doi.org/10.1212/CPJ.0000000000001060
doi: 10.1212/CPJ.0000000000001060
pubmed: 34840876
pmcid: 8610525
Trunfio M, Atzori C, Pasquero M et al (2022) Patterns of cerebrospinal fluid Alzheimer’s dementia biomarkers in people living with HIV: cross-sectional study on associated factors according to viral control neurological confounders and neurocognition. Viruses. https://doi.org/10.3390/v14040753
doi: 10.3390/v14040753
pubmed: 35458483
pmcid: 9031633
Wozniak MA, Shipley SJ, Combrinck M et al (2005) Productive herpes simplex virus in brain of elderly normal subjects and Alzheimer’s disease patients. J Med Virol 75:300–306. https://doi.org/10.1002/jmv.20271
doi: 10.1002/jmv.20271
pubmed: 15602731
Wozniak MA, Itzhaki RF, Shipley SJ et al (2007) Herpes simplex virus infection causes cellular beta-amyloid accumulation and secretase upregulation. Neurosci Lett 429:95–100. https://doi.org/10.1016/j.neulet.2007.09.077
doi: 10.1016/j.neulet.2007.09.077
pubmed: 17980964
Wozniak MA, Mee AP, Itzhaki RF (2009) Herpes simplex virus type 1 DNA is located within Alzheimer’s disease amyloid plaques. J Pathol 217:131–138. https://doi.org/10.1002/path.2449
doi: 10.1002/path.2449
pubmed: 18973185
Wozniak MA, Frost AL, Preston CM et al (2011) Antivirals reduce the formation of key Alzheimer’s disease molecules in cell cultures acutely infected with herpes simplex virus type 1. PLoS ONE 6:e25152. https://doi.org/10.1371/journal.pone.0025152
doi: 10.1371/journal.pone.0025152
pubmed: 22003387
pmcid: 3189195
Peter JB, Sevall JS (2001) Review of 3200 serially received CSF samples submitted for type-specific HSV detection by PCR in the reference laboratory setting. Mol Cell Probes 15:177–182. https://doi.org/10.1006/mcpr.2001.0356
doi: 10.1006/mcpr.2001.0356
pubmed: 11352599
DeBiasi RL, Kleinschmidt-DeMasters BK, Richardson-Burns S et al (2002) Central nervous system apoptosis in human herpes simplex virus and cytomegalovirus encephalitis. J Infect Dis 186:1547–1557. https://doi.org/10.1086/345375
doi: 10.1086/345375
pubmed: 12447729
Saldanha J, Sutton RN, Gannicliffe A et al (1986) Detection of HSV1 DNA by in situ hybridisation in human brain after immunosuppression. J Neurol Neurosurg Psychiatry 49:613–619. https://doi.org/10.1136/jnnp.49.6.613
doi: 10.1136/jnnp.49.6.613
pubmed: 3016195
pmcid: 1028840
Letenneur L, Peres K, Fleury H et al (2008) Seropositivity to herpes simplex virus antibodies and risk of Alzheimer’s disease: a population-based cohort study. PLoS ONE 3:e3637. https://doi.org/10.1371/journal.pone.0003637
doi: 10.1371/journal.pone.0003637
pubmed: 18982063
pmcid: 2572852
Lovheim H, Gilthorpe J, Adolfsson R et al (2015) Reactivated herpes simplex infection increases the risk of Alzheimer’s disease. Alzheimers Dement 11:593–599. https://doi.org/10.1016/j.jalz.2014.04.522
doi: 10.1016/j.jalz.2014.04.522
pubmed: 25043910
Alvarez G, Aldudo J, Alonso M et al (2012) Herpes simplex virus type 1 induces nuclear accumulation of hyperphosphorylated tau in neuronal cells. J Neurosci Res 90:1020–1029. https://doi.org/10.1002/jnr.23003
doi: 10.1002/jnr.23003
pubmed: 22252837
Cairns DM, Itzhaki RF, Kaplan DL (2022) Potential involvement of varicella zoster virus in Alzheimer’s disease via reactivation of quiescent herpes simplex virus type 1. J Alzheimers Dis 88:1189–1200. https://doi.org/10.3233/JAD-220287
doi: 10.3233/JAD-220287
pubmed: 35754275
Itzhaki RF, Dobson CB (2002) Alzheimer’s disease and herpes. CMAJ 167:13
pubmed: 12137067
pmcid: 116625
Lophatananon A, Mekli K, Cant R et al (2021) Shingles, zostavax vaccination and risk of developing dementia: a nested case-control study-results from the UK Biobank cohort. BMJ Open 11:e045871. https://doi.org/10.1136/bmjopen-2020-045871
doi: 10.1136/bmjopen-2020-045871
pubmed: 34625411
pmcid: 8504358
De Chiara G, Piacentini R, Fabiani M et al (2019) Recurrent herpes simplex virus-1 infection induces hallmarks of neurodegeneration and cognitive deficits in mice. PLoS Pathog 15:e1007617. https://doi.org/10.1371/journal.ppat.1007617
doi: 10.1371/journal.ppat.1007617
pubmed: 30870531
pmcid: 6417650
Itzhaki RF (2022) Does antiherpetic antiviral therapy reduce the risk of dementia? Nat Rev Neurol 18:63–64. https://doi.org/10.1038/s41582-021-00596-4
doi: 10.1038/s41582-021-00596-4
pubmed: 34873309
Tzeng NS, Chung CH, Lin FH et al (2018) Anti-herpetic medications and reduced risk of dementia in patients with herpes simplex virus infections-a nationwide, population-based cohort study in Taiwan. Neurotherapeutics 15:417–429. https://doi.org/10.1007/s13311-018-0611-x
doi: 10.1007/s13311-018-0611-x
pubmed: 29488144
pmcid: 5935641
Jang H, Boltz D, Sturm-Ramirez K et al (2009) Highly pathogenic H5N1 influenza virus can enter the central nervous system and induce neuroinflammation and neurodegeneration. Proc Natl Acad Sci USA 106:14063–14068. https://doi.org/10.1073/pnas.0900096106
doi: 10.1073/pnas.0900096106
pubmed: 19667183
pmcid: 2729020
Jurgens HA, Amancherla K, Johnson RW (2012) Influenza infection induces neuroinflammation, alters hippocampal neuron morphology, and impairs cognition in adult mice. J Neurosci 32:3958–3968. https://doi.org/10.1523/JNEUROSCI.6389-11.2012
doi: 10.1523/JNEUROSCI.6389-11.2012
pubmed: 22442063
pmcid: 3353809
Mizuguchi M (2013) Influenza encephalopathy and related neuropsychiatric syndromes. Influenza Other Respir Viruses 7:67–71. https://doi.org/10.1111/irv.12177
doi: 10.1111/irv.12177
pubmed: 24215384
pmcid: 6492655
Imfeld P, Toovey S, Jick SS et al (2016) Influenza infections and risk of Alzheimer’s disease. Brain Behav Immun 57:187–192. https://doi.org/10.1016/j.bbi.2016.03.014
doi: 10.1016/j.bbi.2016.03.014
pubmed: 27006278
Verreault R, Laurin D, Lindsay J et al (2001) Past exposure to vaccines and subsequent risk of Alzheimer’s disease. CMAJ 165:1495–1498
pubmed: 11762573
pmcid: 81665
Liu JC, Hsu YP, Kao PF et al (2016) Influenza vaccination reduces dementia risk in chronic kidney disease patients: a population-based cohort study. Medicine (Baltimore) 95:e2868. https://doi.org/10.1097/MD.0000000000002868
doi: 10.1097/MD.0000000000002868
pubmed: 26945371
Luo CS, Chi CC, Fang YA et al (2020) Influenza vaccination reduces dementia in patients with chronic obstructive pulmonary disease: a nationwide cohort study. J Investig Med 68:838–845. https://doi.org/10.1136/jim-2019-001155
doi: 10.1136/jim-2019-001155
pubmed: 31941664
Veronese N, Demurtas J, Smith L et al (2022) Influenza vaccination reduces dementia risk: a systematic review and meta-analysis. Ageing Res Rev 73:101534. https://doi.org/10.1016/j.arr.2021.101534
doi: 10.1016/j.arr.2021.101534
pubmed: 34861456
Bukhbinder AS, Ling Y, Hasan O et al (2022) Risk of Alzheimer’s disease following influenza vaccination: a claims-based cohort study using propensity score matching. J Alzheimers Dis 88:1061–1074. https://doi.org/10.3233/JAD-220361
doi: 10.3233/JAD-220361
pubmed: 35723106
pmcid: 9484126
Yang Y, He Z, Xing Z et al (2020) Influenza vaccination in early Alzheimer’s disease rescues amyloidosis and ameliorates cognitive deficits in APP/PS1 mice by inhibiting regulatory T cells. J Neuroinflammation 17:65. https://doi.org/10.1186/s12974-020-01741-4
doi: 10.1186/s12974-020-01741-4
pubmed: 32075657
pmcid: 7029575
Demurtas J, Celotto S, Beaudart C et al (2020) The efficacy and safety of influenza vaccination in older people: an umbrella review of evidence from meta-analyses of both observational and randomized controlled studies. Ageing Res Rev 62:101118. https://doi.org/10.1016/j.arr.2020.101118
doi: 10.1016/j.arr.2020.101118
pubmed: 32565328